Background/Objectives: To evaluate the technical feasibility, safety, and therapeutic outcomes of the transradial approach for drug-eluting bead transarterial chemoembo-lization (DEB-TACE) as a patient-centric alternative to the conventional transfemoral route. Methods: Between August 2018 and August 2022, patients with unresectable hepato-cellular carcinoma (HCC) eligible for DEB-TACE were prospectively enrolled in this study (ClinicalTrials.gov identifier: NCT07160374). To prevent radial artery spasm and occlusion, a standardized intra-arterial cocktail solution containing 3,000 IU of heparin, 200 μg of nitroglycerin, and 2.5 mg of verapamil was administered immediately after sheath insertion. The primary endpoint was technical success without crossover to the femoral approach. Secondary endpoints included safety profile, tumor response, and procedural parameters. Results: A total of 37 patients were enrolled. Technical success was achieved in 100% of patients using the transradial approach, with zero crossover to the transfemoral ap-proach. A single major adverse event (liver abscess) occurred (2.7%). Radial artery pa-tency was preserved in all patients. All patients achieved immediate post-procedural ambulation. The objective response rate was 73% at first follow-up visit (median, 35 days; range, 14–60 days). The mean fluoroscopy time was 24 ± 9 minutes, and the mean dose area product was 142 ± 182 Gy·cm². Conclusions: The transradial approach demonstrated high technical success and a fa-vorable safety profile for DEB-TACE without increasing radiation exposure. These findings suggest that this method represents a feasible and effective alternative to the conventional transfemoral route.